home / stock / jmacu / jmacu news
Apollomics said on Tuesday that the U.S. Food and Drug Administration (FDA) in August granted orphan drug designation to the company's vebreltinib (APL-101) to treat patients with non-small cell lung cancer (NSCLC) with MET genomic tumor aberrations. Apollomics is going public...
FOSTER CITY, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: JMAC), an innovative biopharmaceutical company committed to the discovery and development of mono- and combination-oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) ha...
TAIPEI CITY - ( NewMediaWire ) - October 14, 2022 - Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”) announced today that its sponsor, MP One Investment LLC (the “Sponsor”), deposited an additional payment in the aggregate amount of $1,035,000 (repr...
Maxpro Capital Acquisition ( NASDAQ: JMAC ) has announced that its sponsor, MP One Investment, has requested to extend the date by which the Co. has to consummate a business combination from Oct. 13, 2022 to Jan. 13, 2023 . For this, the Sponsor has notified the Co. that i...
Taipei City - ( NewMediaWire ) - October 07, 2022 - Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”), announced today that its sponsor, MP One Investment LLC (the “Sponsor”), has requested that the Company extend the date by which the Company has to...
– Transaction values Apollomics at pre-money equity value of $899 million – Apollomics is a late-stage clinical biopharmaceutical company developing innovative product candidates for large, unmet medical needs –Broad pipeline of drug candidates across multiple...
Taipei City - ( NewMediaWire ) - November 26, 2021 - Maxpro Capital Acquisition Corp. (“Maxpro” or the “Company”), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or sim...
News, Short Squeeze, Breakout and More Instantly...
Maxpro Capital Acquisition Corp. Units Company Name:
JMACU Stock Symbol:
NASDAQ Market:
FOSTER CITY, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: JMAC), an innovative biopharmaceutical company committed to the discovery and development of mono- and combination-oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) ha...
TAIPEI CITY - ( NewMediaWire ) - October 14, 2022 - Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”) announced today that its sponsor, MP One Investment LLC (the “Sponsor”), deposited an additional payment in the aggregate amount of $1,035,000 (repr...
Taipei City - ( NewMediaWire ) - October 07, 2022 - Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”), announced today that its sponsor, MP One Investment LLC (the “Sponsor”), has requested that the Company extend the date by which the Company has to...